NASDAQ:ONCESpark Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Spark Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $113.57 0.00 (0.00 %) (As of 12/26/2019) Add Compare Share Today's Range$113.57Now: $113.57▼$113.5750-Day Range$113.57MA: $113.57▼$113.5752-Week Range$34.53Now: $113.57▼$114.20Volume8,720 shsAverage Volume419,933 shsMarket Capitalization$4.37 billionP/E RatioN/ADividend YieldN/ABeta2.05 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company's gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. It is also developing other liver-directed gene therapies, including SPK-3006 for Pompe disease; and neurodegenerative disease product candidates to address Huntington's disease and others, as well as TPP1 deficiency, which is a form of Batten disease. The company's preclinical programs targets inherited retinal diseases, including Stargardt's disease. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. It also has licensing and commercialization agreement with Novartis to develop and commercialize voretigene neparvovec outside the United States. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.Read More Beat the Market (BTM) Rank™ 1.0 Analyst's Opinion Consensus RatingSpark Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $114.50, Spark Therapeutics has a potential upside of 0.8% from its current price of $113.57.Amount of Analyst CoverageSpark Therapeutics has received no research coverage in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesSpark Therapeutics has received 519 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSpark Therapeutics has received 443 “underperform” votes. (Add your “underperform” vote.)Community SentimentSpark Therapeutics has received 53.95% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Spark Therapeutics and other stocks. Vote “Outperform” if you believe ONCE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ONCE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSpark Therapeutics does not currently pay a dividend.Dividend GrowthSpark Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Spark Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.00% of the stock of Spark Therapeutics is held by insiders.Percentage Held by Institutions88.37% of the stock of Spark Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Spark Therapeutics are expected to grow in the coming year, from ($5.07) to ($4.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spark Therapeutics is -53.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Spark Therapeutics is -53.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpark Therapeutics has a P/B Ratio of 8.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.07 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ONCE Previous Symbol CUSIPN/A CIK1609351 Webwww.sparktx.com Phone888-772-7560Debt Debt-to-Equity Ratio0.35 Current Ratio4.67 Quick Ratio4.35Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$64.72 million Price / Sales67.59 Cash FlowN/A Price / Cash FlowN/A Book Value$13.15 per share Price / Book8.64Profitability EPS (Most Recent Fiscal Year)($2.11) Net Income$-78,820,000.00 Net Margins-358.41% Return on Equity-59.10% Return on Assets-33.13%Miscellaneous Employees368 Outstanding Shares38,520,000Market Cap$4.37 billion Next Earnings DateN/A OptionableOptionable $113.57 0.00 (0.00 %) (As of 12/26/2019) 30 days | 90 days | 365 days | Advanced Chart Receive ONCE News and Ratings via Email Sign-up to receive the latest news and ratings for ONCE and its competitors with MarketBeat's FREE daily newsletter. Spark Therapeutics (NASDAQ:ONCE) Frequently Asked Questions How has Spark Therapeutics' stock price been impacted by COVID-19? Spark Therapeutics' stock was trading at $113.57 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ONCE shares have increased by 0.0% and is now trading at $113.57. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Spark Therapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spark Therapeutics in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Spark Therapeutics. How were Spark Therapeutics' earnings last quarter? Spark Therapeutics Inc (NASDAQ:ONCE) issued its quarterly earnings data on Tuesday, August, 7th. The biotechnology company reported ($0.77) EPS for the quarter, missing the Zacks' consensus estimate of ($0.43) by $0.34. The biotechnology company had revenue of $25.19 million for the quarter, compared to the consensus estimate of $29.44 million. Spark Therapeutics had a negative net margin of 358.41% and a negative return on equity of 59.10%. View Spark Therapeutics' earnings history. What price target have analysts set for ONCE? 2 brokers have issued 12-month price targets for Spark Therapeutics' stock. Their forecasts range from $114.50 to $114.50. On average, they expect Spark Therapeutics' stock price to reach $114.50 in the next twelve months. This suggests a possible upside of 0.8% from the stock's current price. View analysts' price targets for Spark Therapeutics. Has Spark Therapeutics been receiving favorable news coverage? News headlines about ONCE stock have been trending neutral recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Spark Therapeutics earned a daily sentiment score of 0.2 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Spark Therapeutics. Who are some of Spark Therapeutics' key competitors? Some companies that are related to Spark Therapeutics include BioNTech (BNTX), Qiagen (QGEN), argenx (ARGX), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Novavax (NVAX), Repligen (RGEN), Crispr Therapeutics (CRSP), Acceleron Pharma (XLRN), Allogene Therapeutics (ALLO), Adaptive Biotechnologies (ADPT), bluebird bio (BLUE), China Biologic Products (CBPO), Iovance Biotherapeutics (IOVA) and Halozyme Therapeutics (HALO). View all competitors. What other stocks do shareholders of Spark Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Spark Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Brainstorm Cell Therapeutics (BCLI), Gilead Sciences (GILD), AbbVie (ABBV), Exelixis (EXEL), Netflix (NFLX), Intel (INTC) and Pfizer (PFE). Who are Spark Therapeutics' key executives? Spark Therapeutics' management team includes the following people: Mr. Jeffrey D. Marrazzo, Co-Founder, CEO & Director (Age 40)Dr. Katherine A. High, Co-Founder, Pres, Head of R&D and Director (Age 67)Mr. Stephen W. Webster, Chief Financial Officer (Age 58)Mr. Joseph W. La Barge Esq., J.D., Chief Legal Officer & Sec. (Age 48)Mr. Daniel R. Faga, Chief Bus. Officer (Age 39) When did Spark Therapeutics IPO? (ONCE) raised $88 million in an IPO on Friday, January 30th 2015. The company issued 5,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers. What is Spark Therapeutics' stock symbol? Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE." How do I buy shares of Spark Therapeutics? Shares of ONCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Spark Therapeutics' stock price today? One share of ONCE stock can currently be purchased for approximately $113.57. How big of a company is Spark Therapeutics? Spark Therapeutics has a market capitalization of $4.37 billion and generates $64.72 million in revenue each year. The biotechnology company earns $-78,820,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Spark Therapeutics employs 368 workers across the globe. What is Spark Therapeutics' official website? The official website for Spark Therapeutics is www.sparktx.com. How can I contact Spark Therapeutics? Spark Therapeutics' mailing address is 3737 MARKET STREET SUITE 1300, PHILADELPHIA PA, 19104. The biotechnology company can be reached via phone at 888-772-7560 or via email at [email protected] This page was last updated on 8/11/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
